{"id":2683,"date":"2026-08-26T07:59:47","date_gmt":"2026-08-26T07:59:47","guid":{"rendered":"https:\/\/eieling.com\/?p=2683"},"modified":"2026-08-26T07:59:49","modified_gmt":"2026-08-26T07:59:49","slug":"in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines","status":"publish","type":"post","link":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/","title":{"rendered":"\u5728\u6e1b\u80a5\u85e5\u76db\u884c\u7684\u6642\u4ee3\uff0c\u70ba\u4ec0\u9ebc\u809d\u81df\u8102\u80aa\u76e3\u6e2c\u5df2\u6210\u70ba\u5168\u7403\u6307\u5357\u8a8d\u53ef\u7684\u300c\u57fa\u672c\u9700\u6c42\u300d\uff1f"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>01 Start with an underestimated fact: Fatty liver is not &#8220;suboptimal health&#8221;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>It has already become the most common chronic liver disease.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Many people still think of fatty liver as &#8220;a negligible arrow on a health checkup report.&#8221; But global authoritative data and the latest nomenclature have long redefined it as an epidemic:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to a 2024 epidemiological review by Younossi et al. published in&nbsp;<em>Clinical Gastroenterology and Hepatology<\/em>, approximately&nbsp;<strong>38% of adults worldwide<\/strong>&nbsp;have metabolic dysfunction-associated steatotic liver disease (MASLD), with a prevalence of 7%\u201314% among children and adolescents [1].<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In China, a meta-analysis incorporating 561 studies and covering&nbsp;<strong>6.63 million people<\/strong>&nbsp;showed that the prevalence of MASLD in adults is as high as&nbsp;<strong>30.4%<\/strong>, and it continues to rise \u2014 27.6% before 2010, 31.7% during 2015\u20132019, and surging to&nbsp;<strong>36.5%<\/strong>&nbsp;after 2019 [2].<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">More critical is its&nbsp;<strong>&#8220;silent&#8221; nature<\/strong>: fatty liver causes no pain and goes unnoticed until it progresses to MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis, eventually leading to cirrhosis and liver cancer.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The global scale of overweight and obesity provides the underlying logic for these numbers:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>World Health Organization (WHO) 2022 data showed\u00a0<strong>2.5 billion adults<\/strong>\u00a0were overweight, of whom 890 million were obese; by 2024, the global obese population had exceeded\u00a0<strong>1 billion<\/strong>\u00a0[3][4].<\/li>\n\n\n\n<li>The\u00a0<em>China Nutrition and Chronic Disease Status Report (2020)<\/em>\u00a0showed that 34.3% of adults were overweight and 16.4% were obese \u2014 a combined total exceeding 50%, meaning\u00a0<strong>one in two adults<\/strong>\u00a0is overweight or obese [5].<\/li>\n\n\n\n<li>The 2026 Chinese Obesity Guidelines updated this figure: in 2024, China&#8217;s overweight\/obesity prevalence had reached\u00a0<strong>56.4%<\/strong>, projected to reach\u00a0<strong>70.5%<\/strong>\u00a0(approximately 611 million people) by 2030 [19].<\/li>\n\n\n\n<li>The\u00a0<em>Lancet<\/em>\u00a0Global Burden of Disease Study noted that China has\u00a0<strong>402 million<\/strong>\u00a0overweight and obese adults, ranking\u00a0<strong>first in the world<\/strong>\u00a0[6].<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The conclusion is straightforward:<\/strong><br>Fatty liver is the&nbsp;<strong>leading chronic liver disease in China<\/strong>, and its &#8220;fuel&#8221; \u2014 obesity and metabolic disorders \u2014 is still accelerating.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>02 Evidence-based medicine: Why are guidelines and the FDA all emphasizing &#8220;quantitative monitoring of liver fat&#8221;?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If epidemiological data proves that &#8220;there are enough people,&#8221; the next question is: why do these people need&nbsp;<strong>&#8220;continuous, quantitative&#8221;<\/strong>&nbsp;liver fat monitoring, rather than just a blood test once a year? The answer lies in several recent authoritative documents.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>How much weight loss is needed for liver fat to truly decrease? \u2014 The 2024 Joint Guidelines by Three European Societies give hard metrics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The 2024 MASLD Clinical Practice Guidelines jointly issued by the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) provide a widely cited &#8220;dose-response&#8221; relationship:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Weight loss \u22655%<\/strong>&nbsp;reduces hepatic steatosis;&nbsp;<strong>7%\u201310%<\/strong>&nbsp;improves inflammation;&nbsp;<strong>\u226510%<\/strong>&nbsp;may improve liver fibrosis [7].<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">The clinical implication of this statement is: whether weight loss &#8220;works&#8221; and &#8220;to what extent&#8221; must be answered through quantitative liver fat measurement. The scale only tells you &#8220;how many kilograms you&#8217;ve lost,&#8221; but cannot answer &#8220;how much liver fat has actually decreased&#8221; \u2014 and the latter is the key to determining how far you are from cirrhosis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical studies confirm this: a study published in the&nbsp;<em>Journal of Clinical Investigation<\/em>&nbsp;showed that with approximately 10% weight loss, intrahepatic triglyceride content (IHTG) decreased from 19.4% to 4.5% (<em>P<\/em>&nbsp;&lt; 0.001) [8].<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>China 2026 Guidelines: Quantitative liver fat officially written into obesity diagnostic criteria<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In August 2026, the Chinese Society of Endocrinology of the Chinese Medical Association issued the&nbsp;<em>Guidelines for Long-Term Weight Management and Clinical Application of Pharmacotherapy in Patients with Obesity (2026 Edition)<\/em>. In Table 2 \u2014 &#8220;Common Diagnostic Criteria for Obesity in the Chinese Population&#8221; \u2014 it explicitly lists&nbsp;<strong>&#8220;liver fat content&#8221;<\/strong>&nbsp;as one of the indicators for obesity diagnosis, with quantitative grading standards [19]:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">Detection Method<\/th><th class=\"has-text-align-left\" data-align=\"left\">Grading Criteria<\/th><\/tr><\/thead><tbody><tr><td><strong>Ultrasound Attenuation Parameter (CAP value)<\/strong><\/td><td>Normal: &lt;248 dB\/m; Significant hepatic steatosis: \u2265248 dB\/m; Moderate-severe hepatic steatosis: \u2265268 dB\/m; Severe hepatic steatosis: \u2265294 dB\/m<\/td><\/tr><tr><td><strong>MRI-PDFF<\/strong><\/td><td>Normal: &lt;5%; Mild hepatic steatosis: 5%\u201310%; Moderate: 10%\u201325%; Severe: &gt;25%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This means that within the latest Chinese official diagnostic framework,&nbsp;<strong>&#8220;how much fat is in the liver&#8221;<\/strong>&nbsp;has become a quantifiable indicator for judging obesity and its severity, alongside body weight, waist circumference, and body fat percentage.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA milestone: GLP-1 officially approved for liver disease \u2014 &#8220;monitoring&#8221; becomes a necessary step in medication use<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On&nbsp;<strong>August 15, 2025<\/strong>, the U.S. FDA approved&nbsp;<strong>Wegovy (semaglutide 2.4 mg)<\/strong>&nbsp;for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-severe liver fibrosis (F2\u2013F3) \u2014 making it&nbsp;<strong>the first GLP-1 receptor agonist approved globally for liver disease<\/strong>, and the second MASH treatment approved after resmetirom [9].<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Three details from this approval directly point to the clinical necessity of &#8220;liver fat monitoring&#8221;:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The indication is built upon quantitative imaging assessment<\/strong>: The supporting Phase 3 ESSENCE trial used imaging metrics (MRI-PDFF, etc.) and histological endpoints to quantify improvements in liver fat and fibrosis [9].<\/li>\n\n\n\n<li><strong>ESSENCE trial results<\/strong>: At 72 weeks,\u00a0<strong>63%<\/strong>\u00a0of patients in the semaglutide group achieved MASH resolution without worsening of fibrosis, compared to only\u00a0<strong>34%<\/strong>\u00a0in the placebo group [10].<\/li>\n\n\n\n<li><strong>Accelerated approval = ongoing monitoring required<\/strong>: Because the approval followed the &#8220;surrogate endpoint&#8221; accelerated pathway, regulators require continued post-marketing data collection on clinical benefit \u2014 meaning every patient starting therapy needs a quantifiable liver fat baseline and ongoing follow-up assessments.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The American Association for the Study of Liver Diseases (AASLD) subsequently issued a dedicated practice update on semaglutide for MASLD\/MASH in November 2025, explicitly requiring monitoring of treatment safety and efficacy [11].<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Guidelines endorse &#8220;monitoring&#8221; \u2014 MRI-PDFF is the gold standard, but its cost and accessibility create a gap<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The AASLD 2024 Imaging-Based Noninvasive Assessment Guidelines and the EASL 2024 Guidelines consistently confirm:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MRI-PDFF<\/strong>\u00a0(proton density fat fraction) is the\u00a0<strong>&#8220;gold standard&#8221;<\/strong>\u00a0for non-invasive quantitative liver fat measurement, suitable for grading and monitoring treatment response [7][12].<\/li>\n\n\n\n<li>But it is\u00a0<strong>expensive, reliant on large equipment, and has long appointment wait times<\/strong>\u00a0\u2014 making it unsuitable for high-frequency, continuous, or decentralized monitoring scenarios.<\/li>\n\n\n\n<li>While technologies like the Controlled Attenuation Parameter (CAP) are non-invasive, the AASLD Guidelines also explicitly note that CAP\u00a0<strong>cannot accurately quantify or continuously monitor changes in liver fat<\/strong>\u00a0[13].<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This creates a clear&nbsp;<strong>structural gap<\/strong>: guidelines demand &#8220;continuous, quantitative&#8221; monitoring of liver fat, but the tools that meet this requirement (MRI-PDFF) are both expensive and inaccessible.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>03 Market reality: GLP-1 weight-loss drugs are exploding at a visible pace<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Monitoring demand does not emerge from nowhere \u2014 it is being &#8220;fed&#8221; by an already-validated, high-growth industrial chain.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Global: $132 billion \u2014 and still accelerating<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to data released at the 2026 AMCP Annual Meeting, global GLP-1 drug sales reached approximately&nbsp;<strong>$132 billion<\/strong>&nbsp;in 2025, with&nbsp;<strong>year-over-year growth of 33.5%<\/strong>&nbsp;[14]:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">Drug<\/th><th class=\"has-text-align-left\" data-align=\"left\">2025 Sales<\/th><th class=\"has-text-align-left\" data-align=\"left\">YoY Growth<\/th><\/tr><\/thead><tbody><tr><td>Mounjaro (tirzepatide, diabetes)<\/td><td>$39.1B<\/td><td>+67.1%<\/td><\/tr><tr><td>Zepbound (tirzepatide, weight loss)<\/td><td>$22.9B<\/td><td>+188.7%<\/td><\/tr><tr><td>Wegovy (semaglutide, weight loss)<\/td><td>$18.6B<\/td><td>+29.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The&nbsp;<strong>weight-loss indication<\/strong>&nbsp;is the fastest-growing segment. Grand View Research projects the global GLP-1 weight-loss drug market will grow from $13.8 billion in 2024 to **$48.8 billion by 2030** (CAGR 18.5%) [15]. J.P. Morgan estimates that by 2030, approximately&nbsp;<strong>25 million people<\/strong>&nbsp;in the U.S. alone will be using GLP-1 drugs (up from ~10 million in 2025) [16].<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>China: Penetration rate only ~1% \u2014 the largest gap and fastest growth<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Chinese market shows a classic pattern of&nbsp;<strong>&#8220;low penetration, high growth&#8221;<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Global GLP-1 drug sales exceeded **$50 billion** in 2024, with semaglutide alone contributing ~$25 billion and tirzepatide ~$16 billion [17].<\/li>\n\n\n\n<li>According to China Industrial Research data, China&#8217;s GLP-1 weight-loss drug market is expected to exceed\u00a0<strong>\u00a515 billion<\/strong>\u00a0in 2025, with penetration projected to rise from less than 5% in 2023 to 18%\u201320% [17].<\/li>\n\n\n\n<li>More noteworthy is a striking comparison: China&#8217;s adult obesity rate is 16.4% and overweight rate 34.3%, but GLP-1 penetration among the obese population is only about\u00a0<strong>1%<\/strong>\u00a0[18].<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Medication users are precisely the population that most needs &#8220;liver fat monitoring&#8221;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GLP-1 users and the high-risk population for fatty liver&nbsp;<strong>heavily overlap<\/strong>&nbsp;\u2014 most are overweight or obese, with underlying metabolic disorders. Weight-loss drugs reduce body weight while also changing liver fat; but &#8220;how much has it changed&#8221; can only be known through quantitative monitoring.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Guidelines demand<\/strong>: \u22655% weight loss to reduce steatosis, \u226510% to possibly improve fibrosis [7] \u2014 without quantitative monitoring, you don&#8217;t know which tier you&#8217;re in.<\/li>\n\n\n\n<li><strong>Real-world pain points<\/strong>: scales, body fat analyzers, and ALT blood tests\u00a0<strong>cannot directly reflect liver fat<\/strong>. And MRI-PDFF is both expensive and difficult to schedule.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>&#8220;GLP-1 + liver fat monitoring&#8221;<\/strong>&nbsp;is becoming a new essential combination jointly driven by global guidelines and the FDA.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>04 Conclusion<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">From epidemiological data showing &#8220;hundreds of millions affected,&#8221; to the 2026 Chinese Guidelines writing quantitative liver fat into diagnostic criteria, to the FDA embedding monitoring into the GLP-1 liver disease treatment pathway \u2014&nbsp;<strong>&#8220;quantitative liver fat monitoring&#8221;<\/strong>&nbsp;is transitioning from optional to standard practice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The bottleneck to implementation has always been the gap between&nbsp;<strong>&#8220;gold-standard capability&#8221;<\/strong>&nbsp;and&nbsp;<strong>&#8220;high-frequency, accessible, decentralized deployment.&#8221;<\/strong>&nbsp;How to close this gap is the challenge that the entire industry will need to address together.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>References<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[1] Younossi ZM, et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease.&nbsp;<em>Clin Gastroenterol Hepatol<\/em>. 2024.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39159948\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39159948\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[2] Meta-analysis of MASLD prevalence in Chinese adults (561 studies, 6.63 million people). MedSci.&nbsp;<a href=\"https:\/\/nursing.medsci.cn\/article\/show_article.do?id=5e9e925e5784\" target=\"_blank\" rel=\"noopener\">https:\/\/nursing.medsci.cn\/article\/show_article.do?id=5e9e925e5784<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[3] WHO. Obesity and overweight \u2014 Fact sheet.&nbsp;<a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\" target=\"_blank\" rel=\"noopener\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[4] World Obesity Federation \/ NCD-RisC. Prevalence of obesity.&nbsp;<a href=\"https:\/\/www.worldobesity.org\/about\/about-obesity\/prevalence-of-obesity\" target=\"_blank\" rel=\"noopener\">https:\/\/www.worldobesity.org\/about\/about-obesity\/prevalence-of-obesity<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[5] China Nutrition and Chronic Disease Status Report (2020). China Youth Net.&nbsp;<a href=\"https:\/\/news.youth.cn\/jswx\/202405\/t20240516_15256033.htm\" target=\"_blank\" rel=\"noopener\">https:\/\/news.youth.cn\/jswx\/202405\/t20240516_15256033.htm<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[6]&nbsp;<em>Lancet<\/em>&nbsp;Global Burden of Disease Study (2021). Chinese CDC.&nbsp;<a href=\"https:\/\/literature.chinacdc.cn\/xuekefuwu\/gonggongweishengxueshuredianzhuz\/202503\/t20250311_304818.html\" target=\"_blank\" rel=\"noopener\">https:\/\/literature.chinacdc.cn\/xuekefuwu\/gonggongweishengxueshuredianzhuz\/202503\/t20250311_304818.html<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[7] EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD.&nbsp;<em>J Hepatol<\/em>. 2024;81:492-542.&nbsp;<a href=\"https:\/\/karger.com\/ofa\/article\/17\/4\/374\/908875\/EASL-EASD-EASO-Clinical-Practice-Guidelines-on-the\" target=\"_blank\" rel=\"noopener\">https:\/\/karger.com\/ofa\/article\/17\/4\/374\/908875\/EASL-EASD-EASO-Clinical-Practice-Guidelines-on-the<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[8] Weight loss of 10% reduces IHTG from 19.4% to 4.5%.&nbsp;<em>J Clin Invest<\/em>.&nbsp;<a href=\"https:\/\/www.jci.org\/articles\/view\/174233\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jci.org\/articles\/view\/174233<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[9] FDA Approves Treatment for Serious Liver Disease Known as &#8216;MASH&#8217; (Wegovy approval).&nbsp;<a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash\" target=\"_blank\" rel=\"noopener\">https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[10] Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE).&nbsp;<em>N Engl J Med<\/em>. 2025;392:2089-2099.&nbsp;<a href=\"https:\/\/www.pharmacytimes.com\/view\/semaglutide-receives-fda-approval-for-treatment-of-mash\" target=\"_blank\" rel=\"noopener\">https:\/\/www.pharmacytimes.com\/view\/semaglutide-receives-fda-approval-for-treatment-of-mash<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[11] Semaglutide therapy for MASH: November 2025 updates to AASLD Practice Guidance.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201884\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/41201884\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[12] AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.&nbsp;<em>Hepatology<\/em>. 2024.&nbsp;<a href=\"https:\/\/journals.lww.com\/hep\/fulltext\/10.1097\/hep.0000000000000843\" target=\"_blank\" rel=\"noopener\">https:\/\/journals.lww.com\/hep\/fulltext\/10.1097\/hep.0000000000000843<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[13] AASLD Practice Guidance on the clinical assessment and management of NAFLD.&nbsp;<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10735173\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10735173\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[14] GLP-1 drugs to drive growth (AMCP 2026). Managed Healthcare Executive.&nbsp;<a href=\"https:\/\/www.managedhealthcareexecutive.com\/view\/glp-1-drugs-to-drive-growth-in-obesity-and-diabetes-treatment-amcp-annual-2026\" target=\"_blank\" rel=\"noopener\">https:\/\/www.managedhealthcareexecutive.com\/view\/glp-1-drugs-to-drive-growth-in-obesity-and-diabetes-treatment-amcp-annual-2026<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[15] GLP-1 Agonists Weight Loss Drugs Market Report. Grand View Research.&nbsp;<a href=\"https:\/\/www.grandviewresearch.com\/industry-analysis\/glp-1-agonists-weight-loss-drugs-market-report\" target=\"_blank\" rel=\"noopener\">https:\/\/www.grandviewresearch.com\/industry-analysis\/glp-1-agonists-weight-loss-drugs-market-report<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[16] J.P. Morgan. How Supply and Demand for Weight Loss Drugs is Playing Out in 2026.&nbsp;<a href=\"https:\/\/www.jpmorgan.com\/insights\/global-research\/current-events\/obesity-drugs\" target=\"_blank\" rel=\"noopener\">https:\/\/www.jpmorgan.com\/insights\/global-research\/current-events\/obesity-drugs<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[17] Semaglutide faces new competitors. Beijing News.&nbsp;<a href=\"https:\/\/m.bjnews.com.cn\/detail\/1751333560168858.html\" target=\"_blank\" rel=\"noopener\">https:\/\/m.bjnews.com.cn\/detail\/1751333560168858.html<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[18] Price cuts on semaglutide and tirzepatide. Cailianshe.&nbsp;<a href=\"https:\/\/www.cls.cn\/detail\/2241765\" target=\"_blank\" rel=\"noopener\">https:\/\/www.cls.cn\/detail\/2241765<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">[19] Guidelines for Long-Term Weight Management and Clinical Application of Pharmacotherapy in Patients with Obesity (2026 Edition). Chinese Society of Endocrinology, Chinese Medical Association.&nbsp;<em>Chinese Journal of Endocrinology and Metabolism<\/em>, August 2026, Vol. 42, No. 8.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Eieling Technology<\/strong><br><em>Liver health, at your side<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Named to\u00a0<em>Forbes<\/em>\u00a0&#8220;Asia-Pacific 100 Companies to Watch&#8221; in 2023<\/li>\n\n\n\n<li>CES 2026 Digital Health Innovation Award Winner<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\ud83d\udcde +86 156 0176 5936<br>\ud83c\udf0f&nbsp;<a href=\"https:\/\/www.eieling.com\/\" target=\"_blank\" rel=\"noopener\">www.eieling.com<\/a><br>\u2709&nbsp;info@eieling.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &#8220;suboptimal health&#8221; It has already become the most common chronic liver disease. Many people still think of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.2.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &quot;suboptimal health&quot; It has already become the most common chronic liver disease. Many people still think of\" \/>\n\t<meta name=\"robots\" content=\"max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n\t<meta name=\"author\" content=\"Eieling\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.2.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"zh_TW\" \/>\n\t\t<meta property=\"og:site_name\" content=\"EIELING -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING\" \/>\n\t\t<meta property=\"og:description\" content=\"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &quot;suboptimal health&quot; It has already become the most common chronic liver disease. Many people still think of\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-26T07:59:47+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-26T07:59:49+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &quot;suboptimal health&quot; It has already become the most common chronic liver disease. Many people still think of\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#blogposting\",\"name\":\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \\u201cEssential Need\\u201d Endorsed by Global Guidelines? - EIELING\",\"headline\":\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?\",\"author\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/author\\\/eieling\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/eieling.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/\\u5fae\\u4fe1\\u56fe\\u7247_20260512140204_715_1-scaled.jpg\",\"width\":2560,\"height\":1707},\"datePublished\":\"2026-08-26T07:59:47+00:00\",\"dateModified\":\"2026-08-26T07:59:49+00:00\",\"inLanguage\":\"zh-TW\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#webpage\"},\"articleSection\":\"Blog\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eieling.com\\\/tc\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/#listItem\",\"name\":\"Blog\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/#listItem\",\"position\":2,\"name\":\"Blog\",\"item\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#listItem\",\"name\":\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#listItem\",\"position\":3,\"name\":\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/#listItem\",\"name\":\"Blog\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#organization\",\"name\":\"EIELING\",\"url\":\"https:\\\/\\\/eieling.com\\\/tc\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/author\\\/eieling\\\/#author\",\"url\":\"https:\\\/\\\/eieling.com\\\/tc\\\/author\\\/eieling\\\/\",\"name\":\"Eieling\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/593860068d3dccdfa8a256af87f65c2fe2761b4c5fca4848e92698d0e844df4c?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Eieling\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#webpage\",\"url\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/\",\"name\":\"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \\u201cEssential Need\\u201d Endorsed by Global Guidelines? - EIELING\",\"description\":\"Intro: An evidence-based article \\u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not \\\"suboptimal health\\\" It has already become the most common chronic liver disease. Many people still think of\",\"inLanguage\":\"zh-TW\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/author\\\/eieling\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/author\\\/eieling\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/eieling.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/\\u5fae\\u4fe1\\u56fe\\u7247_20260512140204_715_1-scaled.jpg\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#mainImage\",\"width\":2560,\"height\":1707},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/blog\\\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\\\/#mainImage\"},\"datePublished\":\"2026-08-26T07:59:47+00:00\",\"dateModified\":\"2026-08-26T07:59:49+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#website\",\"url\":\"https:\\\/\\\/eieling.com\\\/tc\\\/\",\"name\":\"EIELING\",\"inLanguage\":\"zh-TW\",\"publisher\":{\"@id\":\"https:\\\/\\\/eieling.com\\\/tc\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"\u5728\u6e1b\u80a5\u85e5\u76db\u884c\u7684\u6642\u4ee3\uff0c\u70ba\u4f55\u809d\u81df\u8102\u80aa\u76e3\u6e2c\u5df2\u6210\u70ba\u5168\u7403\u6307\u5357\u8a8d\u53ef\u7684\u300c\u57fa\u672c\u9700\u6c42\u300d\uff1f - \u827e\u7433","description":"\u5f15\u8a00\uff1a\u672c\u6587\u4ee5\u5be6\u8b49\u91ab\u5b78\u70ba\u57fa\u790e\uff0c\u904b\u7528\u6700\u65b0\u6307\u5f15\u548cFDA\u6587\u4ef6\uff0c\u95e1\u8ff0\u70ba\u4f55\u5b9a\u91cf\u809d\u81df\u8102\u80aa\u76e3\u6e2c\u6b63\u6210\u70ba\u6162\u6027\u75c5\u7ba1\u7406\u7684\u65b0\u6a19\u6e96\u3002 01 \u9996\u5148\u8981\u6307\u51fa\u4e00\u500b\u5e38\u88ab\u4f4e\u4f30\u7684\u4e8b\u5be6\uff1a\u8102\u80aa\u809d\u4e26\u975e\"\u5065\u5eb7\u72c0\u6cc1\u6b20\u4f73\"\uff0c\u5b83\u5df2\u6210\u70ba\u6700\u5e38\u898b\u7684\u6162\u6027\u809d\u75c5\u3002\u8a31\u591a\u4eba\u4ecd\u7136\u8a8d\u70ba\u2026","canonical_url":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/","robots":"max-snippet:-1, max-image-preview:large, max-video-preview:-1","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#blogposting","name":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING","headline":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?","author":{"@id":"https:\/\/eieling.com\/tc\/author\/eieling\/#author"},"publisher":{"@id":"https:\/\/eieling.com\/tc\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/eieling.com\/wp-content\/uploads\/2026\/07\/\u5fae\u4fe1\u56fe\u7247_20260512140204_715_1-scaled.jpg","width":2560,"height":1707},"datePublished":"2026-08-26T07:59:47+00:00","dateModified":"2026-08-26T07:59:49+00:00","inLanguage":"zh-TW","mainEntityOfPage":{"@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#webpage"},"isPartOf":{"@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#webpage"},"articleSection":"Blog"},{"@type":"BreadcrumbList","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/#listItem","position":1,"name":"Home","item":"https:\/\/eieling.com\/tc\/","nextItem":{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/blog\/#listItem","name":"Blog"}},{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/blog\/#listItem","position":2,"name":"Blog","item":"https:\/\/eieling.com\/tc\/blog\/","nextItem":{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#listItem","name":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?"},"previousItem":{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#listItem","position":3,"name":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?","previousItem":{"@type":"ListItem","@id":"https:\/\/eieling.com\/tc\/blog\/#listItem","name":"Blog"}}]},{"@type":"Organization","@id":"https:\/\/eieling.com\/tc\/#organization","name":"EIELING","url":"https:\/\/eieling.com\/tc\/"},{"@type":"Person","@id":"https:\/\/eieling.com\/tc\/author\/eieling\/#author","url":"https:\/\/eieling.com\/tc\/author\/eieling\/","name":"Eieling","image":{"@type":"ImageObject","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/593860068d3dccdfa8a256af87f65c2fe2761b4c5fca4848e92698d0e844df4c?s=96&d=mm&r=g","width":96,"height":96,"caption":"Eieling"}},{"@type":"WebPage","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#webpage","url":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/","name":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING","description":"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not \"suboptimal health\" It has already become the most common chronic liver disease. Many people still think of","inLanguage":"zh-TW","isPartOf":{"@id":"https:\/\/eieling.com\/tc\/#website"},"breadcrumb":{"@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#breadcrumblist"},"author":{"@id":"https:\/\/eieling.com\/tc\/author\/eieling\/#author"},"creator":{"@id":"https:\/\/eieling.com\/tc\/author\/eieling\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/eieling.com\/wp-content\/uploads\/2026\/07\/\u5fae\u4fe1\u56fe\u7247_20260512140204_715_1-scaled.jpg","@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#mainImage","width":2560,"height":1707},"primaryImageOfPage":{"@id":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/#mainImage"},"datePublished":"2026-08-26T07:59:47+00:00","dateModified":"2026-08-26T07:59:49+00:00"},{"@type":"WebSite","@id":"https:\/\/eieling.com\/tc\/#website","url":"https:\/\/eieling.com\/tc\/","name":"EIELING","inLanguage":"zh-TW","publisher":{"@id":"https:\/\/eieling.com\/tc\/#organization"}}]},"og:locale":"zh_TW","og:site_name":"EIELING -","og:type":"article","og:title":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING","og:description":"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &quot;suboptimal health&quot; It has already become the most common chronic liver disease. Many people still think of","og:url":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/","article:published_time":"2026-08-26T07:59:47+00:00","article:modified_time":"2026-08-26T07:59:49+00:00","twitter:card":"summary_large_image","twitter:title":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines? - EIELING","twitter:description":"Intro: An evidence-based article \u2014 using the latest guidelines and FDA documents to explain why quantitative liver fat monitoring is becoming the new standard in chronic disease management. 01 Start with an underestimated fact: Fatty liver is not &quot;suboptimal health&quot; It has already become the most common chronic liver disease. Many people still think of"},"aioseo_meta_data":{"post_id":"2683","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-08-26 07:59:49","updated":"2026-08-26 08:19:09","focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/eieling.com\/tc\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/eieling.com\/tc\/blog\/\" title=\"Blog\">Blog<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tIn the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an \u201cEssential Need\u201d Endorsed by Global Guidelines?\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/eieling.com\/tc\/"},{"label":"Blog","link":"https:\/\/eieling.com\/tc\/blog\/"},{"label":"In the Era of Weight-Loss Drugs, Why Has Liver Fat Monitoring Become an &#8220;Essential Need&#8221; Endorsed by Global Guidelines?","link":"https:\/\/eieling.com\/tc\/blog\/in-the-era-of-weight-loss-drugs-why-has-liver-fat-monitoring-become-an-essential-need-endorsed-by-global-guidelines\/"}],"_links":{"self":[{"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/posts\/2683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/comments?post=2683"}],"version-history":[{"count":1,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/posts\/2683\/revisions"}],"predecessor-version":[{"id":2684,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/posts\/2683\/revisions\/2684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/media\/2421"}],"wp:attachment":[{"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/media?parent=2683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/categories?post=2683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eieling.com\/tc\/wp-json\/wp\/v2\/tags?post=2683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}